3-(4-Bromophenyl)-1,2,4-oxadiazole

Catalog No. :
ACXPAR538
CAS No. :
16013-07-3
Molecular Formula :
C8H5BrN2O
Molecular Weight :
225.04

IUPAC Name:3-(4-bromophenyl)-1,2,4-oxadiazole

3-(4-Bromophenyl)-1,2,4-oxadiazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg98%$76.00Login to see priceInquiryInquiry
1g98%$159.00Login to see priceInquiryInquiry
5g98%$566.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-(4-Bromophenyl)-1,2,4-oxadiazole
IUPAC Name3-(4-bromophenyl)-1,2,4-oxadiazole
MDL No.B181844
Molecular FormulaC8H5BrN2O
Molecular Weight225.04
SMILESBrC1=CC=C(C2=NOC=N2)C=C1
InChI KeyOOQNOWMRFJKXTC-UHFFFAOYSA-N
Synonym3-(4-Bromophenyl)-1,2,4-oxadiazole | 16013-07-3 | MFCD09027281 | SCHEMBL16907809 | 4-bromophenyl-1,2,4-oxadiazole | DTXSID40649573 | AC4585 | AKOS015835677 | BS-21613 | SY024851 | 1,2,4-Oxadiazole, 3-(4-bromophenyl)- | CS-0205368 | EN300-79231 | 3-(4-bromophenyl)-1,2,4-oxadiazole,
CAS No.16013-07-3
PubChem CID25307214

Safety Data

Pictogram
CorrosiveToxicHarmful or irritant
Signal Word
Danger
Hazard Statement(s)
H301-H315-H318-H335
Precautionary Statement(s)
P233-P260-P261-P264-P270-P271-P280-P301+P310-P302+P352-P304-P304+P340-P305+P351+P338-P310-P312-P321-P330-P332+P313-P340-P362-P403-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACXPAR538 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACLTOO748 route compound structure diagram
    ACLTOO748960373-05-1 In Stock
  4. Then
  5. ACXPAR538 route product structure diagram
    ACXPAR53816013-07-3
Inquiry

2. ACXPAR538 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACXPAR538 route product structure diagram
    ACXPAR53816013-07-3
Inquiry

Comments (0)